Sanofi SA - Asset Resilience Ratio
Sanofi SA (SAN) has an Asset Resilience Ratio of 6.04% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check SAN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Sanofi SA's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Sanofi SA to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Sanofi SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SAN market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €7.66 Billion | 6.04% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €7.66 Billion | 6.04% |
Asset Resilience Insights
- Limited Liquidity: Sanofi SA maintains only 6.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Sanofi SA Industry Peers by Asset Resilience Ratio
Compare Sanofi SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Chongqing Lummy Pharmaceutical
SHE:300006 |
Drug Manufacturers - General | -0.19% |
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507 |
Drug Manufacturers - General | 26.41% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for Sanofi SA (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Sanofi SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.99% | €7.59 Billion ≈ $8.87 Billion |
€126.81 Billion ≈ $148.25 Billion |
+0.97pp |
| 2024-12-31 | 5.01% | €6.66 Billion ≈ $7.78 Billion |
€132.80 Billion ≈ $155.25 Billion |
-0.93pp |
| 2023-12-31 | 5.95% | €7.52 Billion ≈ $8.79 Billion |
€126.46 Billion ≈ $147.85 Billion |
-3.70pp |
| 2022-12-31 | 9.64% | €12.02 Billion ≈ $14.05 Billion |
€124.58 Billion ≈ $145.65 Billion |
+1.50pp |
| 2021-12-31 | 8.15% | €9.79 Billion ≈ $11.45 Billion |
€120.24 Billion ≈ $140.58 Billion |
-3.79pp |
| 2020-12-31 | 11.94% | €13.67 Billion ≈ $15.98 Billion |
€114.53 Billion ≈ $133.90 Billion |
+11.56pp |
| 2019-12-31 | 0.38% | €426.00 Million ≈ $498.04 Million |
€112.74 Billion ≈ $131.80 Billion |
+0.20pp |
| 2018-12-31 | 0.18% | €199.00 Million ≈ $232.65 Million |
€111.41 Billion ≈ $130.25 Billion |
+0.10pp |
| 2017-12-31 | 0.08% | €77.00 Million ≈ $90.02 Million |
€99.81 Billion ≈ $116.69 Billion |
+0.05pp |
| 2016-12-31 | 0.03% | €31.00 Million ≈ $36.24 Million |
€104.67 Billion ≈ $122.37 Billion |
+0.02pp |
| 2015-12-31 | 0.01% | €13.00 Million ≈ $15.20 Million |
€102.32 Billion ≈ $119.62 Billion |
+0.00pp |
| 2014-12-31 | 0.01% | €9.00 Million ≈ $10.52 Million |
€97.39 Billion ≈ $113.86 Billion |
-0.05pp |
| 2013-12-31 | 0.06% | €59.00 Million ≈ $68.98 Million |
€96.06 Billion ≈ $112.30 Billion |
+0.01pp |
| 2012-12-31 | 0.06% | €56.00 Million ≈ $65.47 Million |
€100.41 Billion ≈ $117.39 Billion |
+0.02pp |
| 2011-12-31 | 0.03% | €35.00 Million ≈ $40.92 Million |
€100.67 Billion ≈ $117.69 Billion |
+0.01pp |
| 2010-12-31 | 0.03% | €23.00 Million ≈ $26.89 Million |
€85.26 Billion ≈ $99.68 Billion |
-0.32pp |
| 2009-12-31 | 0.35% | €277.00 Million ≈ $323.84 Million |
€80.05 Billion ≈ $93.59 Billion |
-0.21pp |
| 2008-12-31 | 0.56% | €403.00 Million ≈ $471.15 Million |
€71.99 Billion ≈ $84.16 Billion |
+0.44pp |
| 2007-12-31 | 0.12% | €83.00 Million ≈ $97.04 Million |
€69.00 Billion ≈ $80.67 Billion |
-0.03pp |
| 2006-12-31 | 0.15% | €108.35 Million ≈ $126.67 Million |
€74.27 Billion ≈ $86.83 Billion |
-0.21pp |
| 2005-12-31 | 0.36% | €310.71 Million ≈ $363.25 Million |
€86.94 Billion ≈ $101.65 Billion |
-0.40pp |
| 2004-12-31 | 0.76% | €647.68 Million ≈ $757.21 Million |
€85.41 Billion ≈ $99.85 Billion |
-32.34pp |
| 2003-12-31 | 33.09% | €3.22 Billion ≈ $3.77 Billion |
€9.73 Billion ≈ $11.38 Billion |
+1.97pp |
| 2002-12-31 | 31.12% | €2.95 Billion ≈ $3.44 Billion |
€9.47 Billion ≈ $11.07 Billion |
-10.68pp |
| 2001-12-31 | 41.80% | €4.17 Billion ≈ $4.87 Billion |
€9.97 Billion ≈ $11.65 Billion |
+7.74pp |
| 2000-12-31 | 34.06% | €2.67 Billion ≈ $3.12 Billion |
€7.84 Billion ≈ $9.17 Billion |
+2.49pp |
| 1999-12-31 | 31.57% | €2.15 Billion ≈ $2.52 Billion |
€6.82 Billion ≈ $7.98 Billion |
-- |
About Sanofi SA
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting aga… Read more